YIH
AEON icon

Y-Intercept (HK)’s AEON Biopharma AEON Stock Holding History

Y-Intercept (HK)’s Portfolio AEON Stock Details AEON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-291
Closed -$22K – 1253
2024
Q2 		$22K Buy
291
+152
+109% +$36.2K ﹤0.01% 1317
2024
Q1 		$116K Buy
+139
New +$101K 0.01% 1261

Other funds holding AEON

PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FAM
Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
CG
Caprock Group Boise, Idaho $5.22B AUM 42.47% 1-Year Est. Return

Y-Intercept (HK)'s AEON Position: Q3 2024 in Review

Y-Intercept (HK) sold out of AEON Biopharma (AEON) in Q3 2024, closing a stake of 291 shares — an estimated $22K sold.

Y-Intercept (HK) first reported a position in AEON in Q1 2024 and held it in 2 quarters. The position peaked at $116K in Q1 2024. 30 funds tracked by Wall St. Rank hold AEON as of Q3 2024.

  • Y-Intercept (HK) reported no remaining AEON Biopharma position as of Q3 2024 after selling out during the quarter.
  • Y-Intercept (HK) sold 291 AEON Biopharma shares in Q3 2024, an estimated $22K.
  • Y-Intercept (HK) first reported a position in AEON Biopharma in Q1 2024 and held it in 2 quarters.
  • Y-Intercept (HK)'s AEON Biopharma position peaked at $116K in Q1 2024.
  • 30 funds tracked by Wall St. Rank held AEON Biopharma as of Q3 2024.

Based on Y-Intercept (HK)'s 13F filing for Q3 2024, filed 15 Nov 2024.